Vivarelli, Marina http://orcid.org/0000-0002-2448-1959
Samuel, Susan
Coppo, Rosanna
Barratt, Jonathan
Bonilla-Felix, Melvin
Haffner, Dieter
Gibson, Keisha
Haas, Mark
Abdel-Hafez, Maher Ahmed
Adragna, Marta
Brogan, Paul
Kim, Siah
Liu, Isaac
Liu, Zhi-Hong
Mantan, Mukta
Shima, Yuko
Shimuzu, Masaki
Shen, Qian
Trimarchi, Hernan
Hahn, Deirdre
Hodson, Elisabeth
Pfister, Ken
Alladin, Areefa
Boyer, Olivia
Nakanishi, Koichi
,
Article History
Received: 1 February 2024
Revised: 8 August 2024
Accepted: 8 August 2024
First Online: 27 September 2024
Declarations
:
: MV has participated in sponsored trials and has received speaker/consultant fees from Alexion, Apellis, Bayer, Roche, Chinook, Novartis, Travere, Glaxo, Vifor, Biocryst, and PureSpring. These did not influence the content of this guideline.SS has no conflict of interest to declare.RC has no conflict of interest to declare.JB reports research grants from Argenx, Calliditas Therapeutics, Chinook Therapeutics, Galapagos, GlaxoSmithKline, Novartis, and Travere Therapeutics and is medical and/or scientific advisor to Alnylam Pharmaceuticals, Argenx, Astellas Pharma, BioCryst Pharmaceuticals, Calliditas Therapeutics, Chinook Therapeutics, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, UCB, Vera Therapeutics, and Visterra.MBF holds Advisor-Speaker contracts with Natera and Sanofi Pharmaceutical.DH has no conflicts of interest to declare.KG reports consultative roles with Travere Inc. and research support from Travere Inc., Roche Inc., and Aurinia Inc.MH has received consulting fees from Argenx, AstraZeneca, CareDx, Novartis, Travere, and Vera Therapeutics.MAAH has no conflict of interest to disclose.MA is a member of advisory boards and participates in scientific events receiving honoraria from Alexion and Gador. This did not influence the content of this guideline.PB has no conflict of interest to declare.SK has no conflict of interest to declare.ILD has no conflict of interest to declare.ZHL has no conflict of interest to declare.MM has no conflict of interest to declare.YS has no conflict of interest to disclose.MS has no conflict of interest to declare.QS has no conflict of interest to declare.HT has no conflict of interest to declare.DH has no conflict of interest to declare.EH has no conflict of interest to declare.KP has no conflict of interest to declare.AA has no conflict of interest to declare.OB has participated in sponsored trials and has received speaker/consultant fees from Alexion, Alnylam, Biocodex, Novartis, PureSpring, Travere, and Vifor. These did not influence the content of this guideline.KN has participated in sponsored trials and has received speaker/consultant fees from AstraZeneca, Alexion, KyowaKirin, Novartis, Sumitomo Pharma, and Chugai Pharmaceutical. These did not influence the content of this guideline.